Biomedical subjects
Publications and source records attributed to W Nagel.
Explore the source record for details and available documents.
The possible participation of mitochondria-rich cells in transepithelial Na+ transport across frog skin under "physiological conditions" (low apical [Na+], open circuited) was analysed by recording electrophysiological parameters from principal cells with intracellular microelectrodes and using measurement of Rb+ uptake into the epithelial cells from the serosal side via the Na+/K+-ATPase. It was observed that transport perturbation with amiloride induced changes in the apical potential difference and fractional apical resistance in principal cells, observations which are compatible with the notion that the essential fraction of transcellular current flow occurs across these cells. Amiloride-inhibitable uptake of Rb+ was also restricted to principal cells, the amount being about equivalent to the predicted rate of K+ recycling via the Na+/K+-ATPase. The results indicate that principal cells are responsible for transepithelial Na+ transport irrespective of the experimental conditions. Flow of Na+ across mitochondria-rich cells appears to be negligible.
Explore the source record for details and available documents.
In the present study, the in vitro activity of titanocenedichloride, a novel anticancer metal complex, in eleven primary renal cell carcinoma (RCC) specimens was evaluated by an adenosine triphosphate (ATP) bioluminescence assay. Compared to standard antineoplastic agents such as cisplatin, doxorubicin, mitoxantrone and vinblastine, titanocenedichloride was found to exhibit higher cytotoxicity. Four tumors showed strong sensitivity to the new agent. Three of them were resistant to conventional cytostatics. These findings indicated a lack of cross-resistance between titanocenedichloride and both natural compounds as well as platin analogues. Since mitoxantrone was also found to exhibit marked antineoplastic activity with no evidence of cross-resistance to titanocenedichloride, the combination of both drugs in RCC should be evaluated further with additional in vitro studies.